Company Analysis
Sign in

Kymera Therapeutics, Inc. (KYMR)

Nasdaq: KYMR · Biological Products, (No Diagnostic Substances) · Watertown, MA · filing with the SEC since 2020
Full chart Alerts Compare
Grade5.1
◀ Past 6.2● Present 5.3▶ Future 3.6
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$39.2M-16.7%
Net income-$311M-39.1%
Earnings per share$-3.69-23.8%
Operating cash flow-$233M-19.7%
Cash$357M+196.9%
Debtn/a
Shareholders’ equity$1.58B+89.0%
Shares, diluted84.5M+12.6%
Return on equity-19.7%
The recordfrom its filings
Filings in 2026143
Newest filingOct 29 · 10-Q
Annual reportFeb 26, 2026
Quarterly reportOct 29, 2026
Next report due10-K by Mar 1
Insider sales, 12 months$479M
Insider buys, 12 months$173M
Patents granted34
Filer categoryLarge accelerated filer
Trailing twelve months to Sep 2026Revenue $102MNet income -$349MCash from operations -$288Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
19202122232425
As filed, in USD. Nothing here is a forecast.

News

Oct 29, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Oct 29, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Oct 1, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 4, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton KYMR · research, not advice